These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26955275)

  • 1. Suvorexant: a promising, novel treatment for insomnia.
    Lee-Iannotti JK; Parish JM
    Neuropsychiatr Dis Treat; 2016; 12():491-5. PubMed ID: 26955275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
    Keks NA; Hope J
    Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant.
    Norman JL; Anderson SL
    Nat Sci Sleep; 2016; 8():239-47. PubMed ID: 27471419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of suvorexant in the management of insomnia.
    Sutton EL
    Drug Des Devel Ther; 2015; 9():6035-42. PubMed ID: 26648692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suvorexant in insomnia: efficacy, safety and place in therapy.
    Rhyne DN; Anderson SL
    Ther Adv Drug Saf; 2015 Oct; 6(5):189-95. PubMed ID: 26478806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
    Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
    Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia.
    Han AH; Burroughs CR; Falgoust EP; Hasoon J; Hunt G; Kakazu J; Lee T; Kaye AM; Kaye AD; Ganti L
    Health Psychol Res; 2022; 10(5):67898. PubMed ID: 36726477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
    Janto K; Prichard JR; Pusalavidyasagar S
    J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suvorexant: scientifically interesting, utility uncertain.
    Keks NA; Hope J; Keogh S
    Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
    Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
    Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
    J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.
    Cui D; Cabalu T; Yee KL; Small J; Li X; Liu B; Maciolek C; Smith S; Liu W; McCrea JB; Prueksaritanont T
    Xenobiotica; 2016 Oct; 46(10):882-95. PubMed ID: 26864332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.